Splitomicin
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Splitomicin是Sir2p的选择性抑制剂,IC50值为60 μM。Splitomicin也是fMLP诱导的自由基抑制剂,IC50值为40.79 ± 9.85 μM[1,3]。
对Sir2p的HDA的抑制最可能的机制是通过Splitomicin使Sir2p的表型改变。Splitomicin 直接影响Sir2p的脱乙酰酶活性。此外,Splitomicin特定地抑制fMLP诱导的超氧化物阴离子的释放。
在体外,Splitomicin抑制NAD+依赖的Sir2蛋白的组蛋白脱乙酰活性,IC50值为60 μM。从过表达酵母SIR2的hst2菌株中提取的全酵母细胞存在的情况下,使用一个[3H]乙酰化的组蛋白H4肽,测量NAD+依赖的游离[3H]醋酸的释放,获得一个细胞提取物。结果表明Splitomicin的直接影响Sir2p的脱乙酰酶活性。此外,在不同的Splitomicin浓度下,使用流式细胞分析仪观察fMLP(1 μM)或PMA(100 nM))诱导的中性粒细胞,研究细胞内超氧化物阴离子的产生。Splitomicin抑制fMLP诱导的Mac-1表达并提高人中性粒细胞中cAMP水平[1,3]。
Splitomicin的萘基可能负责对血小板的抑制作用。通过使用人类血小板,研究Splitomicin对血小板聚集的抑制作用,监控凝血酶(0.1 U/ml)、胶原蛋白(2 μg/ml)、花生四烯酸(0.5 mM)、U46619(2 μM)或ADP(10 μM)诱导的血小板聚集和ATP的释放。Splitomicin以浓度依赖方式抑制血小板聚集。Splitomicin提高cAMP水平,当Splitomicin(150 μM)结合PGE1(0.5 μM)时,这种抑制效应增强。Splitomicin对血小板聚集的抑制机制可能是通过抑制环AMP磷酸二酯酶活性、细胞内随后的钙离子的运动、TXB2的形成和ATP的释放来增加环AMP水平[2]。
参考文献:
[1]. Bedalov A, Gatbonton T, Irvine WP, et al. Identification of a small molecule inhibitor of Sir2p. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98(26): 15113-15118.
[2]. Liu FC, Liao CH, Chang YW, et al. Splitomicin suppresses human platelet aggregation via inhibition of cyclic AMP phosphodiesterase and intracellular Ca++ release. Thrombosis Research, 2009, 124(2): 199-207.
[3]. Liu FC, Day YJ, Liou JT, et al. Splitomicin inhibits fMLP-induced superoxide anion production in human neutrophils by activate cAMP/PKA signaling inhibition of ERK pathway. European Journal of Pharmacology, 2012, 688: 68-75.
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 198.22 |
Cas No. | 5690-03-9 |
Formula | C13H10O2 |
Solubility | insoluble in H2O; ≥44.2 mg/mL in EtOH with ultrasonic; ≥9.05 mg/mL in DMSO |
Chemical Name | 1,2-dihydrobenzo[f]chromen-3-one |
SDF | Download SDF |
Canonical SMILES | C1CC(=O)OC2=C1C3=CC=CC=C3C=C2 |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |